Britain’s healthcare cost agency has recommended against using Bayer’s new prostate cancer drug Xofigo on the state health service because the German firm did not provide evidence on how well it worked compared to other therapies. The draft guidance from the National Institute for Health and Care Excellence (NICE), issued on Monday, is now subject to consultation. “We are disappointed not to able to recommend this drug, but we have to be confident that its benefits justify its considerable cost,” said NICE Chief Executive Andrew Dillon.
Help employers find you! Check out all the jobs and post your resume.
